Microbot Medical Announces Brigham and Women's Hospital as a Site for Its Pivotal Human Clinical Trial
Microbot Medical Announces Brigham and Women's Hospital as a Site for Its Pivotal Human Clinical Trial
BRAINTREE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announces that Brigham and Women's Hospital (BWH), a leading academic medical center located in Boston, Massachusetts, will participate as a clinical trial site for the pivotal human clinical trial as part of its Investigational Device Exemption ("IDE") application for its LIBERTY Endovascular Robotic Surgical System. Dr. Dmitry Rabkin, MD, PhD (Assistant Chief, Division of Angiography & Interventional Radiology) has been selected as principal investigator at BWH. "We are excited to participate in the clinical evaluation of this innovative technology," said Dr. Rabkin. BWH has completed the Site Initiation Visit, during which BWH clinical staff was trained on the clinical study protocols. In addition, a shipment of LIBERTY investigational units arrived at BWH this week for the clinical trial.
2024年6月17日，馬薩諸塞州波士頓市的主流學術醫療中心、Brigham and Women's Hospital（BWH）將參與作爲臨床試驗站點的重大人類臨床試驗，作爲其Investigational Device Exemption（"IDE"）申請的一部分。Microbot Medical（納斯達克：MBOT）今天宣佈了這一消息。BWH的副主任Dmitry Rabkin MD、PhD（介入放射學分部助理主任）被選爲主要研究員。Rabkin博士表示："我們很高興參與這項創新科技的臨床評估。" BWH已經完成了現場評估，BWH的臨床工作人員已經接受了臨床研究協議的培訓。此外，本週還交付了LIBERTY探驗設備以供臨床試驗使用。
"We are pleased to work with Dr. Rabkin and the team at Brigham and Women's Hospital on this clinical study." commented Harel Gadot, CEO, President and Chairman of Microbot Medical. "We believe their commitment to research and the advancement of science make them an ideal clinical study site."
Microbot Medical的首席執行官、總裁和董事長Harel Gadot表示："我們很高興與Rabkin博士和Brigham and Women's Hospital合作進行這項臨床研究。我們相信他們對研究和科學進展的承諾使他們成爲理想的臨床研究站點。"
The Company is in the process of engaging additional leading centers to participate in the clinical trial.
公司正在與其他領先的中心聯繫，參與臨床試驗。
About Microbot Medical
關於Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a clinical- stage medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.
Microbot Medical Inc.（納斯達克：MBOT）是一家臨床醫療器械公司，專注於改善患者的臨床預後和通過人體內自然和人工管腔提高醫療設備的易用性。
The Investigational LIBERTY Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY Endovascular Robotic Surgical System's remote operation has the potential to be the first system to democratize endovascular interventional procedures.
擬議中的LIBERTY內科手術機器人系統（調查裝置豁免申請）。LIBERTY的測試目的是通過消除大型、笨重的複雜的資本設備，同時減少放射線暴露和外科醫生的負擔，改進目前在內科手術機器人中使用機器人技術的方法。公司相信，遠程操作具有成爲民主化內臟介入手術程序的第一個系統的潛力。關於Microbot Medical的更多信息，請訪問www.microbotmedical.com
Further information about Microbot Medical is available at http://www.microbotmedical.com.
"與管理層表達的其他關於未來預期、信念、目標、計劃或前景的聲明並非歷史事實（即，包括最終招股書補充中控制成本的描述），除非納斯達克或其他執法機構還要求否認，否則您不應將其視爲準確的說明。因爲這些聲明涉及未來事件的風險和不確定性，無法保證實際結果將不會與這些聲明中所述的實際結果有所不同。除非另有規定，否則Microbot Medical不承擔更新前瞻性聲明的責任。"Hingham公司於2024年6月3日Global Newswire發佈.
Safe Harbor
免責聲明
Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic Surgical System, the outcome of its studies to evaluate the LIBERTY Endovascular Robotic Surgical System, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, including whether the Company's pivotal study in humans is successful, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, any lingering uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.
未來財務和/或運營結果、研究、技術、臨床開發以及Microbot Medical Inc.及其子公司的潛在機會的陳述，以及其他關於未來期望、信懇智能、目標、計劃或前景的其他陳述，都構成《1995年私人證券訴訟改革法》和聯邦證券法的前瞻性陳述。任何不是歷史事實（包括但不限於包含諸如“將”、“相信”、“計劃”、“預計”和“估計”之類的字眼的陳述）也應視爲前瞻性陳述。前瞻性陳述涉及風險和不確定性，包括但不限於市場環境、LIBERTY內科手術機器人系統的開發和/或商業化風險，以及其評估LIBERTY內科手術機器人系統的研究結果。LIBERTY內科手術機器人系統的評估結果。該公司認爲，調查的LIBERTY內部循環機器人手術系統的遠程操作有潛力成爲第一個民主化的內部循環介入手術系統。www.sec.gov微型機器人醫療公司聲明除非法律要求否則不承擔更新這些前瞻性聲明的任何意圖或義務。
Investor Contact:
投資者聯繫：
Michal Efraty
米哈爾·埃夫拉蒂
Source: Microbot Medical Inc.
來源：微型機器人醫療公司
譯文內容由第三人軟體翻譯。